Valeant Gets FDA Panel Recommendation for Psoriasis Drug
July 19 2016 - 5:48PM
Dow Jones News
By Wallace Witkowski
Valeant Pharmaceuticals International Inc. (VRX) said late
Tuesday that a Food and Drug Administration advisory committee
voted unanimously to recommend approval for its psoriasis treatment
brodalumab.
Valeant said the FDA's Dermatologic and Ophthalmic Drugs
Advisory Committee voted 18 to 0 to approve brodalumab to treat
moderate-to-severe plaque psoriasis.
The FDA is not bound to its panels' recommendation but generally
follows their recommendations.
Valeant has a license to market brodalumab in the U.S. from
AstraZeneca PLC (AZN).
(END) Dow Jones Newswires
July 19, 2016 17:33 ET (21:33 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Aug 2024 to Sep 2024
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Sep 2023 to Sep 2024
